Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP

Hong Ding, Andrew G. Howarth, Malarvannan Pannirselvam, Todd J. Anderson, David L. Severson, William B. Wiehler, Christopher Triggle, Balwant S. Tuana

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The Type 2 diabetic db/db mouse experiences vascular dysfunction typified by changes in the contraction and relaxation profiles of small mesenteric arteries (SMAs). Contractions of SMAs from the db/db mouse to the α1-adrenoceptor agonist phenylephrine (PE) were significantly enhanced, and acetylcholine (ACh)-induced relaxations were significantly depressed. Drug treatment of db/db mice with a nonthiazolidinedione peroxisome prolifetor-activated receptor-γ agonist and insulin sensitizing agent 2-[2-(4-phenoxy-2-propylphenoxy)ethyl]indole-5-acetic acid (COOH) completely prevented the changes in endothelium-dependent relaxation, but, with the discontinuation of therapy, endothelial dysfunction returned. Dysfunctional SMAs were found to specifically upregulate the expression of a 35-kDa isoform of sarcolemmal membrane-associated protein (SLMAP), which is a component of the excitation-contraction coupling apparatus and implicated in the regulation of membrane function in muscle cells. Real-time PCR revealed high SLMAP mRNA levels in the db/db microvasculature, which were markedly downregulated during COOH treatment but elevated again when drug therapy was discontinued. These data reveal that the microvasculature in db/db mice undergoes significant changes in vascular function with the endothelial component of vascular dysfunction specifically correlating with the overexpression of SLMAP. Thus changes in SLMAP expression may be an important indicator for microvascular disease associated with Type 2 diabetes.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume289
Issue number1 58-1
DOIs
Publication statusPublished - Jul 2005
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Mesenteric Arteries
Tail
Membrane Proteins
Blood Vessels
Microvessels
Excitation Contraction Coupling
Peroxisomes
Insulin Receptor
Phenylephrine
Adrenergic Receptors
Muscle Cells
Acetylcholine
Endothelium
Real-Time Polymerase Chain Reaction
Protein Isoforms
Up-Regulation
Therapeutics
Down-Regulation
Drug Therapy

Keywords

  • Gene expression
  • Mice
  • Microvascular function
  • Sarcolemmal membrane-associated protein

ASJC Scopus subject areas

  • Physiology

Cite this

Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP. / Ding, Hong; Howarth, Andrew G.; Pannirselvam, Malarvannan; Anderson, Todd J.; Severson, David L.; Wiehler, William B.; Triggle, Christopher; Tuana, Balwant S.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 289, No. 1 58-1, 07.2005.

Research output: Contribution to journalArticle

Ding, Hong ; Howarth, Andrew G. ; Pannirselvam, Malarvannan ; Anderson, Todd J. ; Severson, David L. ; Wiehler, William B. ; Triggle, Christopher ; Tuana, Balwant S. / Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP. In: American Journal of Physiology - Heart and Circulatory Physiology. 2005 ; Vol. 289, No. 1 58-1.
@article{8d38edff5151417cb53288a7af8b3f4f,
title = "Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP",
abstract = "The Type 2 diabetic db/db mouse experiences vascular dysfunction typified by changes in the contraction and relaxation profiles of small mesenteric arteries (SMAs). Contractions of SMAs from the db/db mouse to the α1-adrenoceptor agonist phenylephrine (PE) were significantly enhanced, and acetylcholine (ACh)-induced relaxations were significantly depressed. Drug treatment of db/db mice with a nonthiazolidinedione peroxisome prolifetor-activated receptor-γ agonist and insulin sensitizing agent 2-[2-(4-phenoxy-2-propylphenoxy)ethyl]indole-5-acetic acid (COOH) completely prevented the changes in endothelium-dependent relaxation, but, with the discontinuation of therapy, endothelial dysfunction returned. Dysfunctional SMAs were found to specifically upregulate the expression of a 35-kDa isoform of sarcolemmal membrane-associated protein (SLMAP), which is a component of the excitation-contraction coupling apparatus and implicated in the regulation of membrane function in muscle cells. Real-time PCR revealed high SLMAP mRNA levels in the db/db microvasculature, which were markedly downregulated during COOH treatment but elevated again when drug therapy was discontinued. These data reveal that the microvasculature in db/db mice undergoes significant changes in vascular function with the endothelial component of vascular dysfunction specifically correlating with the overexpression of SLMAP. Thus changes in SLMAP expression may be an important indicator for microvascular disease associated with Type 2 diabetes.",
keywords = "Gene expression, Mice, Microvascular function, Sarcolemmal membrane-associated protein",
author = "Hong Ding and Howarth, {Andrew G.} and Malarvannan Pannirselvam and Anderson, {Todd J.} and Severson, {David L.} and Wiehler, {William B.} and Christopher Triggle and Tuana, {Balwant S.}",
year = "2005",
month = "7",
doi = "10.1152/ajpheart.00037.2005",
language = "English",
volume = "289",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "1 58-1",

}

TY - JOUR

T1 - Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP

AU - Ding, Hong

AU - Howarth, Andrew G.

AU - Pannirselvam, Malarvannan

AU - Anderson, Todd J.

AU - Severson, David L.

AU - Wiehler, William B.

AU - Triggle, Christopher

AU - Tuana, Balwant S.

PY - 2005/7

Y1 - 2005/7

N2 - The Type 2 diabetic db/db mouse experiences vascular dysfunction typified by changes in the contraction and relaxation profiles of small mesenteric arteries (SMAs). Contractions of SMAs from the db/db mouse to the α1-adrenoceptor agonist phenylephrine (PE) were significantly enhanced, and acetylcholine (ACh)-induced relaxations were significantly depressed. Drug treatment of db/db mice with a nonthiazolidinedione peroxisome prolifetor-activated receptor-γ agonist and insulin sensitizing agent 2-[2-(4-phenoxy-2-propylphenoxy)ethyl]indole-5-acetic acid (COOH) completely prevented the changes in endothelium-dependent relaxation, but, with the discontinuation of therapy, endothelial dysfunction returned. Dysfunctional SMAs were found to specifically upregulate the expression of a 35-kDa isoform of sarcolemmal membrane-associated protein (SLMAP), which is a component of the excitation-contraction coupling apparatus and implicated in the regulation of membrane function in muscle cells. Real-time PCR revealed high SLMAP mRNA levels in the db/db microvasculature, which were markedly downregulated during COOH treatment but elevated again when drug therapy was discontinued. These data reveal that the microvasculature in db/db mice undergoes significant changes in vascular function with the endothelial component of vascular dysfunction specifically correlating with the overexpression of SLMAP. Thus changes in SLMAP expression may be an important indicator for microvascular disease associated with Type 2 diabetes.

AB - The Type 2 diabetic db/db mouse experiences vascular dysfunction typified by changes in the contraction and relaxation profiles of small mesenteric arteries (SMAs). Contractions of SMAs from the db/db mouse to the α1-adrenoceptor agonist phenylephrine (PE) were significantly enhanced, and acetylcholine (ACh)-induced relaxations were significantly depressed. Drug treatment of db/db mice with a nonthiazolidinedione peroxisome prolifetor-activated receptor-γ agonist and insulin sensitizing agent 2-[2-(4-phenoxy-2-propylphenoxy)ethyl]indole-5-acetic acid (COOH) completely prevented the changes in endothelium-dependent relaxation, but, with the discontinuation of therapy, endothelial dysfunction returned. Dysfunctional SMAs were found to specifically upregulate the expression of a 35-kDa isoform of sarcolemmal membrane-associated protein (SLMAP), which is a component of the excitation-contraction coupling apparatus and implicated in the regulation of membrane function in muscle cells. Real-time PCR revealed high SLMAP mRNA levels in the db/db microvasculature, which were markedly downregulated during COOH treatment but elevated again when drug therapy was discontinued. These data reveal that the microvasculature in db/db mice undergoes significant changes in vascular function with the endothelial component of vascular dysfunction specifically correlating with the overexpression of SLMAP. Thus changes in SLMAP expression may be an important indicator for microvascular disease associated with Type 2 diabetes.

KW - Gene expression

KW - Mice

KW - Microvascular function

KW - Sarcolemmal membrane-associated protein

UR - http://www.scopus.com/inward/record.url?scp=21644432539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644432539&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00037.2005

DO - 10.1152/ajpheart.00037.2005

M3 - Article

VL - 289

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 1 58-1

ER -